1054579-82-6Relevant articles and documents
NOVEL OXIME DERIVATIVES
-
Page/Page column 6-7, (2012/02/06)
The present invention relates to novel oxime derivatives of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.
NOVEL OXIME DERIVATIVES
-
Page/Page column 16, (2010/08/08)
The present invention relates to novel oxime derivatives of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.
Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119
Semple, Graeme,Fioravanti, Beatriz,Pereira, Guillherme,Calderon, Imelda,Uy, Jane,Choi, Karoline,Xiong, Yifeng,Ren, Albert,Morgan, Michael,Dave, Vibha,Thomsen, William,Unett, David J.,Xing, Charles,Bossie, Stuart,Carroll, Chris,Chu, Zhi-Liang,Grottick, Andrew J.,Hauser, Erin K.,Leonard, James,Jones, Robert M.
supporting information; experimental part, p. 5172 - 5175 (2009/07/01)
GPR119 is a rhodopsin-like GPCR expressed in pancreatic β-cells and incretin releasing cells in the GI tract. As with incretins, GPR119 increases cAMP levels in these cell types, thus making it a highly attractive potential target for the treatment of dia